

NOVEN PHARMACEUTICALS INC
 Form 4
 June 05, 2008

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Yetter Wayne P.

(Last) (First) (Middle)

C/O NOVEN
 PHARMACEUTICALS,
 INC., 11960 SW 144TH STREET

(Street)

MIAMI, FL 33186

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 NOVEN PHARMACEUTICALS
 INC [NOVN]

3. Date of Earliest Transaction
 (Month/Day/Year)
 06/03/2008

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock (\$\$.0001 par value)	06/03/2008		P	10,000 A	\$ 11.78	21,192	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
 (9-02)

Edgar Filing: NOVEN PHARMACEUTICALS INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Table with columns: 1. Title of Derivative Security (Instr. 3), 2. Conversion or Exercise Price of Derivative Security, 3. Transaction Date (Month/Day/Year), 3A. Deemed Execution Date, if any (Month/Day/Year), 4. Transaction Code (Instr. 8), 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5), 6. Date Exercisable and Expiration Date (Month/Day/Year), 7. Title and Amount of Underlying Securities (Instr. 3 and 4), 8. Price of Derivative Security (Instr. 5), 9. Number of Derivative Securities Owned Beneficially (Instr. 5), 10. Derivative Security Beneficially Owned (Instr. 5), 11. Reporting Person's Relationship to the Issuer (Instr. 4), 12. Date of Report (Instr. 4), 13. Transaction Type (Instr. 3 and 4), 14. Derivative Security Description (Instr. 3 and 4), 15. Issuer Name (Instr. 3 and 4), 16. Issuer CUSIP Number (Instr. 3 and 4), 17. Issuer Name (Instr. 3 and 4), 18. Issuer CUSIP Number (Instr. 3 and 4), 19. Issuer Name (Instr. 3 and 4), 20. Issuer CUSIP Number (Instr. 3 and 4), 21. Issuer Name (Instr. 3 and 4), 22. Issuer CUSIP Number (Instr. 3 and 4), 23. Issuer Name (Instr. 3 and 4), 24. Issuer CUSIP Number (Instr. 3 and 4), 25. Issuer Name (Instr. 3 and 4), 26. Issuer CUSIP Number (Instr. 3 and 4), 27. Issuer Name (Instr. 3 and 4), 28. Issuer CUSIP Number (Instr. 3 and 4), 29. Issuer Name (Instr. 3 and 4), 30. Issuer CUSIP Number (Instr. 3 and 4), 31. Issuer Name (Instr. 3 and 4), 32. Issuer CUSIP Number (Instr. 3 and 4), 33. Issuer Name (Instr. 3 and 4), 34. Issuer CUSIP Number (Instr. 3 and 4), 35. Issuer Name (Instr. 3 and 4), 36. Issuer CUSIP Number (Instr. 3 and 4), 37. Issuer Name (Instr. 3 and 4), 38. Issuer CUSIP Number (Instr. 3 and 4), 39. Issuer Name (Instr. 3 and 4), 40. Issuer CUSIP Number (Instr. 3 and 4), 41. Issuer Name (Instr. 3 and 4), 42. Issuer CUSIP Number (Instr. 3 and 4), 43. Issuer Name (Instr. 3 and 4), 44. Issuer CUSIP Number (Instr. 3 and 4), 45. Issuer Name (Instr. 3 and 4), 46. Issuer CUSIP Number (Instr. 3 and 4), 47. Issuer Name (Instr. 3 and 4), 48. Issuer CUSIP Number (Instr. 3 and 4), 49. Issuer Name (Instr. 3 and 4), 50. Issuer CUSIP Number (Instr. 3 and 4), 51. Issuer Name (Instr. 3 and 4), 52. Issuer CUSIP Number (Instr. 3 and 4), 53. Issuer Name (Instr. 3 and 4), 54. Issuer CUSIP Number (Instr. 3 and 4), 55. Issuer Name (Instr. 3 and 4), 56. Issuer CUSIP Number (Instr. 3 and 4), 57. Issuer Name (Instr. 3 and 4), 58. Issuer CUSIP Number (Instr. 3 and 4), 59. Issuer Name (Instr. 3 and 4), 60. Issuer CUSIP Number (Instr. 3 and 4), 61. Issuer Name (Instr. 3 and 4), 62. Issuer CUSIP Number (Instr. 3 and 4), 63. Issuer Name (Instr. 3 and 4), 64. Issuer CUSIP Number (Instr. 3 and 4), 65. Issuer Name (Instr. 3 and 4), 66. Issuer CUSIP Number (Instr. 3 and 4), 67. Issuer Name (Instr. 3 and 4), 68. Issuer CUSIP Number (Instr. 3 and 4), 69. Issuer Name (Instr. 3 and 4), 70. Issuer CUSIP Number (Instr. 3 and 4), 71. Issuer Name (Instr. 3 and 4), 72. Issuer CUSIP Number (Instr. 3 and 4), 73. Issuer Name (Instr. 3 and 4), 74. Issuer CUSIP Number (Instr. 3 and 4), 75. Issuer Name (Instr. 3 and 4), 76. Issuer CUSIP Number (Instr. 3 and 4), 77. Issuer Name (Instr. 3 and 4), 78. Issuer CUSIP Number (Instr. 3 and 4), 79. Issuer Name (Instr. 3 and 4), 80. Issuer CUSIP Number (Instr. 3 and 4), 81. Issuer Name (Instr. 3 and 4), 82. Issuer CUSIP Number (Instr. 3 and 4), 83. Issuer Name (Instr. 3 and 4), 84. Issuer CUSIP Number (Instr. 3 and 4), 85. Issuer Name (Instr. 3 and 4), 86. Issuer CUSIP Number (Instr. 3 and 4), 87. Issuer Name (Instr. 3 and 4), 88. Issuer CUSIP Number (Instr. 3 and 4), 89. Issuer Name (Instr. 3 and 4), 90. Issuer CUSIP Number (Instr. 3 and 4), 91. Issuer Name (Instr. 3 and 4), 92. Issuer CUSIP Number (Instr. 3 and 4), 93. Issuer Name (Instr. 3 and 4), 94. Issuer CUSIP Number (Instr. 3 and 4), 95. Issuer Name (Instr. 3 and 4), 96. Issuer CUSIP Number (Instr. 3 and 4), 97. Issuer Name (Instr. 3 and 4), 98. Issuer CUSIP Number (Instr. 3 and 4), 99. Issuer Name (Instr. 3 and 4), 100. Issuer CUSIP Number (Instr. 3 and 4)

Reporting Owners

Table with columns: Reporting Owner Name / Address, Relationships (Director, 10% Owner, Officer, Other). Entry: Yetter Wayne P., C/O NOVEN PHARMACEUTICALS, INC., 11960 SW 144TH STREET, MIAMI, FL 33186, X

Signatures

/s/ Wayne P. Yetter 06/05/2008
**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.